+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Vaccine for Children Market by Vaccine Type, Distribution Channel, Age Group, Dose Regimen, End User - Global Forecast to 2030- Product Image
Respiratory Syncytial Virus Vaccine for Children Market by Vaccine Type, Distribution Channel, Age Group, Dose Regimen, End User - Global Forecast to 2030- Product Image
Sale

Respiratory Syncytial Virus Vaccine for Children Market by Vaccine Type, Distribution Channel, Age Group, Dose Regimen, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081999
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pediatric RSV vaccine market is at a crucial juncture, driven by advances in immunization technology, heightened awareness of infant vulnerability, and intensified collaborations across the value chain. As stakeholders align to address unmet needs, effective strategies for market entry, resilience, and adoption are increasingly central to both public health and commercial success.

Market Snapshot: Pediatric RSV Vaccine Opportunity

This market report highlights the global landscape for respiratory syncytial virus (RSV) vaccines targeting infants and young children. Fueled by escalating hospitalization rates and persistent respiratory complications, demand for effective RSV prevention tools is rising sharply. Recent breakthroughs in vaccine development—particularly in mRNA and subunit technologies—are transforming the trajectory toward clinic adoption, opening doors for pharmaceutical and biotech stakeholders. Early adoption is most prominent in regions with robust public health mandates and established reimbursement pathways, while innovation and regulatory fast-tracking are enhancing competitive agility. The market’s evolving segmentation and entry barriers signal significant growth potential for adaptable players poised to navigate complex international environments.

Pediatric RSV Vaccine Market Scope & Segmentation

The report’s comprehensive scope encompasses all principal market segments and emerging trends shaping the RSV immunization landscape.

  • Vaccine Technologies: Live attenuated vaccines, monoclonal antibodies, mRNA vaccines, subunit vaccines (including protein subunit and virus-like particle formats), and vector-based platforms.
  • Distribution Channels: Clinic pharmacies, hospital pharmacies, online and retail pharmacies.
  • Patient Age Groups: 0 to 6 months (full-term and preterm infants), 6 to 12 months, and 12 to 24 months.
  • Dose Regimens: Single-dose, two-dose, and three-dose series.
  • End Users: Ambulatory care centers, clinics, private and public hospitals.
  • Geographic Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (spanning the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Industry Stakeholders: Leading companies covered: AstraZeneca plc, Sanofi S.A., Pfizer Inc., GlaxoSmithKline plc, Moderna, Inc., Bavarian Nordic A/S, Janssen Pharmaceuticals, Inc., Meissa Vaccines, Inc., BioNTech SE, and CureVac N.V.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Targeted vaccine launches are aligning with acute healthcare system pressures, supporting risk mitigation and improved pediatric outcomes.
  • Collaboration is accelerating platform innovation, with biotech and big pharma actors sharing resources and infrastructure to fast-track clinical timelines.
  • Regulatory flexibility is fostering rapid market access, as agencies adjust approval frameworks for conditional authorizations and integrate digital health for post-market oversight.
  • Comprehensive segmentation enables developers to tailor dosing, distribution, and access strategies to distinct infant and toddler cohorts, optimizing immunization uptake.
  • Corporate deals—including licensing, co-development, and acquisition—are diversifying portfolios and reducing commercialization risk across all stages of innovation.
  • Regional disparities in public health policy, infrastructure, and funding drive distinct adoption pathways, requiring nuanced go-to-market plans for multinational entrants.

Tariff Impact: Addressing U.S. Measures for Vaccine Viability

The application of new U.S. tariffs on imported biologic reagents and specialized raw materials commencing in 2025 has noticeably increased pediatric RSV vaccine production costs. Manufacturers are revising supply chain strategies to mitigate longer lead times and buffer inventory, while also adjusting procurement processes to secure favorable contract manufacturing terms. These dynamics influence both payer negotiations and R&D prioritization, reinforcing the need for proactive tariff management and engagement with policy stakeholders.

Research Methodology & Data Validation

This analysis is grounded in detailed quantitative and qualitative research. The framework combines public sources such as regulatory filings and tariff schedules with interviews involving clinical, policy, and manufacturing experts. Industry databases and regional health authority reports inform segmentation and competitive landscape insights, while strategic hypotheses are validated through market participant workshops and multi-stage peer review.

Why This Report Matters for Executive Leadership

  • Informs portfolio prioritization and investment strategies by mapping technology trends and risk factors across key segments.
  • Equips stakeholders with actionable market intelligence to navigate regulatory, supply chain, and payer challenges in pediatric vaccination.
  • Offers context-driven guidance for strategic partnerships, distribution optimization, and adaptation to regional drivers that shape competitive advantage.

Conclusion

Decision-makers seeking to capitalize on the pediatric RSV vaccine opportunity must balance innovation, resilience, and multi-stakeholder engagement. This report provides a strategic foundation for navigating emerging complexities and positioning for sustainable growth across global markets.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Syncytial Virus Vaccine for Children Market, by Age Group
8.1. Introduction
8.2. 0 to 6 Months
8.2.1. Full-term Infants
8.2.2. Premature Infants
8.3. 1 to 5 Years
8.3.1. Children with Asthma
8.3.2. Healthy Children
8.4. 6 to 12 Months
8.4.1. Healthy Children
8.4.2. Immunocompromised Children
9. Respiratory Syncytial Virus Vaccine for Children Market, by Type of Vaccine
9.1. Introduction
9.2. Live Attenuated Vaccine
9.2.1. Intramuscular Administration
9.2.2. Intranasal Administration
9.3. Monoclonal Antibody
9.3.1. Newer Generation Antibodies
9.3.2. Palivizumab
9.4. Subunit Vaccine
9.4.1. Peptide-based Vaccine
9.4.2. Protein-based Vaccine
10. Respiratory Syncytial Virus Vaccine for Children Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Private Hospitals
10.2.2. Public Hospitals
10.3. Online Providers
10.3.1. Direct Sale Websites
10.3.2. E-commerce Platforms
10.4. Retail Pharmacies
10.4.1. Independent Pharmacies
10.4.2. Supermarket Pharmacies
11. Respiratory Syncytial Virus Vaccine for Children Market, by Type of Manufacturer
11.1. Introduction
11.2. Big Pharmaceutical Companies
11.2.1. Established RSV Vaccines Makers
11.2.2. Potential Entrants in RSV Market
11.3. Biotech Firms
11.3.1. Established Biotech Firms
11.3.2. Start-ups
11.4. Generic Drug Manufacturers
11.4.1. International Players
11.4.2. Local Players
12. Respiratory Syncytial Virus Vaccine for Children Market, by Mode of Action
12.1. Introduction
12.2. Prophylactic
12.2.1. Preventive Antibodies
12.2.2. Preventive Vaccines
12.3. Therapeutic
12.3.1. Therapeutic Monoclonal Antibodies
12.3.2. Therapeutic Vaccines
13. Americas Respiratory Syncytial Virus Vaccine for Children Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Respiratory Syncytial Virus Vaccine for Children Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. AstraZeneca plc
16.3.3. Bavarian Nordic A/S
16.3.4. BiondVax Pharmaceuticals Ltd.
16.3.5. BioPharms Inc.
16.3.6. Clarus Therapeutics, Inc.
16.3.7. GlaxoSmithKline plc
16.3.8. GSK Biologicals SA
16.3.9. Johnson & Johnson (Janssen Pharmaceuticals)
16.3.10. Johnson Matthey Fine Chemicals
16.3.11. MedImmune, LLC (AstraZeneca)
16.3.12. Merck & Co., Inc.
16.3.13. Moderna Inc.
16.3.14. Novavax, Inc.
16.3.15. Pfizer Inc.
16.3.16. ReViral Ltd.
16.3.17. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY FULL-TERM INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PREMATURE INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY CHILDREN WITH ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HEALTHY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HEALTHY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY IMMUNOCOMPROMISED CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INTRANASAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY NEWER GENERATION ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PALIVIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PEPTIDE-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROTEIN-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DIRECT SALE WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ESTABLISHED RSV VACCINES MAKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY POTENTIAL ENTRANTS IN RSV MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ESTABLISHED BIOTECH FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY START-UPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INTERNATIONAL PLAYERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LOCAL PLAYERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PREVENTIVE ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 125. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 127. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 128. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 129. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 130. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 131. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 132. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 133. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 135. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 136. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 137. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 138. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 139. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 140. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 141. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 143. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 144. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 149. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 151. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 152. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 156. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 157. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 158. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 161. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 162. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 222. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 224. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 225. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 226. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 227. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 228. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 229. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 230. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 233. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 234. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 235. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 236. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 237. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 238. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 240. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 241. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 242. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 243. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 244. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 245. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 246. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 247. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 248. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 249. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 252. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 253. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 254. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 255. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 256. INDIA RESPIRATORY SYNCYTIAL VIR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Respiratory Syncytial Virus Vaccine for Children market report include:
  • AstraZeneca plc
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • Bavarian Nordic A/S
  • Janssen Pharmaceuticals, Inc.
  • Meissa Vaccines, Inc.
  • BioNTech SE
  • CureVac N.V.

Related Topics

Related Reports

Respiratory Syncytial Virus Vaccine for the Elderly Market by End User, Distribution Channel, Vaccine Type, Route Of Administration, Age Cohort - Global Forecast to 2030 - Product Image

Respiratory Syncytial Virus Vaccine for the Elderly Market by End User, Distribution Channel, Vaccine Type, Route Of Administration, Age Cohort - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Respiratory Syncytial Virus Vaccine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2025 - Product Image

Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.